Actinogen Medical (ASX:ACW)

Executive Summary

Actinogen Medical is an Australian ASX-listed biotech developing Xanamem® (emestedastat), an oral small-molecule inhibitor of brain 11β-HSD1 that lowers intracellular cortisol. The company targets neuro-cognitive and psychiatric disorders, with lead indications in Alzheimer’s disease, major depressive disorder (MDD), and Fragile X syndrome. By reducing cortisol stress at the cellular level, Xanamem aims to address a key driver of neurodegeneration and cognitive decline. The platform is underpinned by compelling preclinical data and early clinical signals, positioning Actinogen as a unique player in the neurology space. Currently in Phase 2 development, Actinogen is advancing multiple proof-of-concept trials. Recent progress includes successful dose-finding and safety studies, enabling the initiation of larger efficacy trials. The company maintains a lean operation with fewer than 50 employees, relying on strategic partnerships and non-dilutive funding. Key upcoming catalysts include data readouts from the Alzheimer’s Phase 2 trial and potential expansion into MDD and Fragile X. With a differentiated mechanism and broad applicability, Actinogen Medical represents an early-stage but high-upside investment opportunity in the neuropsychiatric arena.

Upcoming Catalysts (preview)

• Q4 2026Top-line Phase 2 data for Xanamem in Alzheimer’s disease50% success
• Q2 2027Initiation of Phase 2 trial in major depressive disorder60% success
• 2026Regulatory update or IND submission for Fragile X syndrome40% success